info@birdgroup.be

Crohn

Ziekte van Crohn

 

REScUE

Loss of RESponse to Ustekinumab treated by dose Escalation
EudraCT number: 2018-004269-14
Includeert momenteel
Onderzoeker: Dr. Peter Bossuyt

 

REScUE-OLE

An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn’s disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation study (REScUE-OLE)
EudraCT Number: 2021-000345-41
Includeert momenteel
Onderzoeker: Dr. Lieven Pouillon

 

I-CARE

Ibd CAncer and seRious infections in Europe
EudraCT NUMBER: 2014-004728-23
Lopende studie
Onderzoeker: Prof. Dr. Laurent Peyrin-Biroulet,
Onderzoekers voor België: Prof. Dr. Jean-François Rahier - Dr. Filip Baert

 

PACIFIC

Study of the inter-individual variation of PhArmaCo-kinetics of Infliximab during treatment Induction in patients with Crohn’s disease and ulcerative Colitis (PACIFIC)
EudraCT Number: 2015-004618-10
Voltooid/analyse in uitvoering
Onderzoeker: Prof. Dr. Denis Franchimont

 

SPARE

A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy.
EudraCT- Number: 2014-002311-41
Voltooid/analyse in uitvoering
Onderzoeker: Prof. Dr. Edouard Louis